Relevant to development of a therapeutic strategy, we have found that either canertinib or the clinically available ErbB inhibitor lapatinib combined with BCR/ABL inhibitors resulted increased cell death of ErbB2+Ph+ALL cells (Fig. 7). The gene discussed is EGFR; the disease is acute lymphoblastic leukemia.